Learning Objectives

By the end of this chapter, learners will be able to:
1. Implement standardized IV corticosteroid protocols for various glomerular diseases
2. Safely administer rituximab infusions with appropriate premedication and monitoring
3. Execute cyclophosphamide protocols for different nephrology indications
4. Manage calcineurin inhibitor therapy with proper monitoring and dose adjustments
5. Coordinate plasmapheresis protocols for emergency and elective indications
6. Apply emergency management protocols for nephrology emergencies
7. Implement appropriate monitoring schedules and safety parameters
8. Adjust medications for renal impairment and drug interactions

Introduction and Principles

Medical management in nephrology requires precise execution of complex treatment protocols that often involve potent immunosuppressive medications with significant potential for both benefit and harm. This chapter provides detailed, step-by-step protocols that can be used as practical guides for the safe and effective management of nephrology patients.

The protocols presented here are based on current evidence-based guidelines, expert consensus, and established clinical practice patterns. However, all protocols should be individualized based on patient-specific factors including age, comorbidities, renal function, and concurrent medications. Close collaboration with pharmacy, nursing, and other healthcare team members is essential for safe implementation.

Safety considerations are paramount when implementing these protocols. All patients should have appropriate baseline laboratory studies, contraindications should be carefully assessed, and monitoring schedules must be strictly followed. Emergency protocols and reversal agents should be readily available when administering high-risk therapies.

Documentation of treatment protocols, patient responses, and any adverse events is crucial for quality improvement and patient safety. Standardized order sets and monitoring checklists can help ensure consistent implementation and reduce the risk of errors.

Intravenous Corticosteroid Protocols

Intravenous corticosteroids are the cornerstone of treatment for many acute glomerular diseases and nephrology emergencies. The choice of agent, dosing, and duration depend on the specific indication and severity of disease.

High-Dose Methylprednisolone Protocol (RPGN/Severe GN)

Indications:
– Rapidly progressive glomerulonephritis (all types)
– Severe lupus nephritis (Class III/IV)
– ANCA-associated vasculitis with renal involvement
– Anti-GBM disease
– Severe acute glomerulonephritis

Protocol:
1. Pre-treatment Assessment:
– Complete blood count with differential
– Comprehensive metabolic panel
– Liver function tests
– Urinalysis with microscopy
– Chest X-ray
– Screen for active infections
– Blood pressure monitoring
– Weight and fluid status assessment

2. Dosing Regimen:
   – Methylprednisolone 500-1000 mg IV daily for 3-5 days
   – Administer over 30-60 minutes in 100-250 mL normal saline
   – Preferred timing: morning administration (8-10 AM)
   – May repeat cycle if inadequate response after 2-4 weeks

3. Premedication:
   – H2 receptor antagonist (ranitidine 50 mg IV or famotidine 20 mg IV)
   – Consider proton pump inhibitor for high-risk patients
   – Antiemetic if history of nausea with steroids

4. Monitoring During Infusion:
   – Vital signs every 15 minutes for first hour
   – Blood glucose monitoring (especially diabetic patients)
   – Watch for signs of fluid overload
   – Monitor for allergic reactions

5. Post-Infusion Management:
   – Transition to oral prednisone 1 mg/kg/day (max 60-80 mg)
   – Begin taper after 2-4 weeks if response achieved
   – Pneumocystis prophylaxis if prolonged high-dose therapy
   – Bone protection with calcium, vitamin D, bisphosphonates

6. Contraindications:
   – Active systemic infection
   – Live virus vaccination within 4 weeks
   – Known hypersensitivity to methylprednisolone
   – Relative: uncontrolled diabetes, severe hypertension

Moderate-Dose Methylprednisolone Protocol (Lupus Nephritis)

Indications:
– Lupus nephritis flare (moderate severity)
– IgA nephropathy with crescents
– Membranoproliferative glomerulonephritis

Protocol:
1. Dosing Regimen:
– Methylprednisolone 250-500 mg IV daily for 3 days
– Administer over 30 minutes in 100 mL normal saline
– Follow with oral prednisone 0.5-1 mg/kg/day

2. Monitoring:
   – Daily weights and fluid balance
   – Blood glucose monitoring
   – Blood pressure checks every 4-6 hours
   – Complete metabolic panel on day 2-3

Rituximab Infusion Protocols

Rituximab is increasingly used in nephrology for various autoimmune conditions. Proper premedication and monitoring are essential to minimize infusion reactions and ensure safety.

Standard Rituximab Protocol for Glomerular Diseases

Indications:
– ANCA-associated vasculitis
– Membranous nephropathy (anti-PLA2R positive)
– Steroid-dependent minimal change disease
– Lupus nephritis (refractory cases)
– Anti-GBM disease (adjunctive therapy)

Pre-Infusion Requirements:
1. Laboratory Studies (within 7 days):
– Complete blood count with differential
– Comprehensive metabolic panel
– Liver function tests
– Hepatitis B surface antigen, core antibody, surface antibody
– Hepatitis C antibody
– HIV testing (if risk factors present)
– Immunoglobulin levels
– CD19+ B-cell count (baseline)

2. Screening for Infections:
   – Chest X-ray
   – Tuberculosis screening (QuantiFERON or TST)
   – Assessment for active infections

3. Contraindications:
   – Active severe infection
   – Severe heart failure (NYHA Class IV)
   – Severe immunodeficiency
   – Live virus vaccination within 4 weeks
   – Pregnancy

Premedication Protocol:
1. 30-60 minutes before infusion:
– Acetaminophen 650-1000 mg PO
– Diphenhydramine 25-50 mg PO or IV
– Methylprednisolone 100 mg IV (or equivalent)

2. For patients with history of severe reactions:
   – Consider additional H2 antagonist
   – May use higher steroid dose (125-250 mg)

Infusion Protocol:
1. First Infusion:
– Start at 50 mg/hour
– If no reaction after 30 minutes, increase to 100 mg/hour
– If no reaction after 30 minutes, increase to 150 mg/hour
– If no reaction after 30 minutes, increase to 200 mg/hour
– Maximum rate: 400 mg/hour

2. Subsequent Infusions (if first infusion tolerated):
   – Start at 100 mg/hour
   – Increase by 100 mg/hour every 30 minutes if tolerated
   – Maximum rate: 400 mg/hour

3. Standard Dosing Regimens:
   – ANCA Vasculitis: 375 mg/m² weekly × 4 doses OR 1000 mg on days 1 and 15
   – Membranous Nephropathy: 1000 mg on days 1 and 15, may repeat at 6 months
   – Lupus Nephritis: 1000 mg on days 1 and 15
   – Minimal Change Disease: 375 mg/m² weekly × 4 doses

Monitoring During Infusion:
1. Vital Signs:
– Every 15 minutes for first hour
– Every 30 minutes for second hour
– Every hour thereafter

2. Watch for Infusion Reactions:
   – Fever, chills, rigors
   – Hypotension or hypertension
   – Bronchospasm, dyspnea
   – Urticaria, angioedema
   – Nausea, vomiting

Management of Infusion Reactions:
1. Mild Reactions (fever, chills, mild hypotension):
– Stop infusion temporarily
– Administer additional acetaminophen and diphenhydramine
– Resume at 50% of previous rate when symptoms resolve

2. Moderate Reactions (significant hypotension, bronchospasm):
   – Stop infusion
   – Administer IV corticosteroids (hydrocortisone 100-200 mg)
   – Bronchodilators if indicated
   – Resume at 25% of previous rate when stable

3. Severe Reactions (anaphylaxis, severe bronchospasm):
   – Stop infusion immediately
   – Epinephrine 0.3-0.5 mg IM
   – High-dose corticosteroids
   – Aggressive supportive care
   – Do not resume infusion

Post-Infusion Monitoring:
1. Immediate (4-6 hours post-infusion):
– Vital signs every hour
– Monitor for delayed reactions
– Assess fluid status

2. Short-term (1-2 weeks):
   – Complete blood count
   – Monitor for cytopenias
   – Assess for infections

3. Long-term (monthly for 6 months):
   – Complete blood count
   – Immunoglobulin levels
   – CD19+ B-cell monitoring
   – Infection surveillance

Cyclophosphamide Protocols

Cyclophosphamide remains an important agent for severe glomerular diseases, available in both oral and intravenous formulations. Proper dosing and monitoring are crucial to maximize efficacy while minimizing toxicity.

Intravenous Cyclophosphamide Protocol (Euro-Lupus Regimen)

Indications:
– Lupus nephritis (Class III/IV)
– ANCA-associated vasculitis
– Severe membranous nephropathy
– Anti-GBM disease

Pre-treatment Assessment:
1. Laboratory Studies:
– Complete blood count with differential
– Comprehensive metabolic panel
– Liver function tests
– Urinalysis
– Pregnancy test (women of childbearing age)

2. Fertility Counseling:
   – Discuss gonadal toxicity risks
   – Consider fertility preservation options
   – Document informed consent

Euro-Lupus Protocol:
1. Dosing:
– 500 mg IV every 2 weeks × 6 doses (total 3 grams)
– Administer in 100-250 mL normal saline over 30-60 minutes
– No dose adjustment for renal function in this regimen

2. Premedication:
   – Ondansetron 4-8 mg IV (antiemetic)
   – Consider dexamethasone 4-8 mg IV for severe nausea

3. Hydration Protocol:
   – Pre-hydration: 500-1000 mL normal saline over 1-2 hours
   – Post-hydration: 500-1000 mL normal saline over 1-2 hours
   – Encourage oral fluid intake (2-3 L/day) for 24-48 hours

4. Mesna Administration:
   – Generally not required for Euro-Lupus doses
   – Consider for patients with history of hemorrhagic cystitis

High-Dose IV Cyclophosphamide Protocol (NIH Regimen)

Indications:
– Severe ANCA-associated vasculitis
– Refractory lupus nephritis
– Anti-GBM disease

Dosing Calculation:
1. Standard Dose:
– 15 mg/kg IV (or 0.5-1.0 g/m²)
– Maximum single dose: 1.2 grams
– Administered monthly × 6 doses, then every 3 months

2. Dose Adjustments:
   – Age >60 years: Reduce by 25%
   – Creatinine >2 mg/dL: Reduce by 25%
   – Previous cyclophosphamide: Reduce by 25%
   – Leukopenia: Hold until WBC >3000/μL

Administration Protocol:
1. Pre-hydration:
– 1-2 L normal saline over 2-4 hours
– Target urine output >100 mL/hour

2. Mesna Protocol:
   – Mesna 20% of cyclophosphamide dose IV at 0, 4, and 8 hours
   – Alternative: Continuous mesna infusion

3. Post-hydration:
   – 1-2 L normal saline over 2-4 hours
   – Continue until urine output >100 mL/hour

Monitoring:
1. During Infusion:
– Vital signs every 30 minutes
– Urine output monitoring
– Watch for allergic reactions

2. Post-Infusion:
   – Complete blood count at 10-14 days
   – Nadir typically occurs at 7-14 days
   – Hold subsequent doses if WBC <3000 or ANC <1000

Oral Cyclophosphamide Protocol

Indications:
– ANCA-associated vasculitis (induction)
– Membranous nephropathy
– Maintenance therapy (selected cases)

Dosing:
1. Standard Dose:
– 2 mg/kg/day PO (round to nearest 25 mg)
– Maximum dose: 150-200 mg/day
– Take in morning with food and plenty of fluids

2. Dose Adjustments:
   – Age >60 years: 1.5 mg/kg/day
   – Creatinine >2 mg/dL: 1.5 mg/kg/day
   – Leukopenia: Reduce or hold based on counts

Monitoring Schedule:
1. Weekly for first month:
– Complete blood count
– Comprehensive metabolic panel
– Urinalysis

2. Every 2 weeks for months 2-3:
   – Complete blood count
   – Basic metabolic panel

3. Monthly thereafter:
   – Complete blood count
   – Comprehensive metabolic panel
   – Urinalysis
   – Liver function tests

Safety Measures:
1. Infection Prevention:
– Monitor for signs of infection
– Consider pneumocystis prophylaxis
– Avoid live vaccines

2. Hemorrhagic Cystitis Prevention:
   – Encourage fluid intake (2-3 L/day)
   – Empty bladder frequently
   – Take medication in morning
   – Monitor for hematuria

3. Fertility Protection:
   – GnRH agonists in women (controversial)
   – Sperm banking in men
   – Regular monitoring of gonadal function

Calcineurin Inhibitor Protocols

Calcineurin inhibitors (cyclosporine and tacrolimus) are important immunosuppressive agents in nephrology, requiring careful dosing and monitoring due to their narrow therapeutic window and potential for nephrotoxicity.

Cyclosporine Protocol

Indications:
– Membranous nephropathy
– Minimal change disease (steroid-dependent)
– Lupus nephritis (maintenance)
– Focal segmental glomerulosclerosis

Initial Dosing:
1. Starting Dose:
– 3-5 mg/kg/day divided into two doses (every 12 hours)
– Take consistently with or without food
– Avoid grapefruit juice and St. John’s wort

2. Target Levels:
   – Trough level (C0): 100-200 ng/mL
   – 2-hour post-dose (C2): 600-1000 ng/mL (if available)

Dose Adjustment Protocol:
1. Week 1-2:
– Check trough level after 3-5 days
– Adjust dose by 25-50 mg increments
– Target therapeutic range

2. Weeks 3-4:
   – Check levels weekly
   – Fine-tune dosing
   – Monitor renal function

3. Maintenance:
   – Check levels every 2-4 weeks initially
   – Monthly once stable
   – Adjust for drug interactions

Monitoring Schedule:
1. Baseline:
– Complete blood count
– Comprehensive metabolic panel
– Liver function tests
– Lipid profile
– Blood pressure
– Urinalysis

2. Weekly for first month:
   – Serum creatinine
   – Cyclosporine level
   – Blood pressure
   – Potassium, magnesium

3. Monthly thereafter:
   – Complete blood count
   – Comprehensive metabolic panel
   – Liver function tests
   – Lipid profile
   – Cyclosporine level

Drug Interactions:
1. Increase Cyclosporine Levels:
– Azole antifungals (fluconazole, itraconazole)
– Macrolide antibiotics (erythromycin, clarithromycin)
– Calcium channel blockers (diltiazem, verapamil)
– Grapefruit juice

2. Decrease Cyclosporine Levels:
   – Anticonvulsants (phenytoin, carbamazepine)
   – Rifampin
   – St. John’s wort
   – Barbiturates

Tacrolimus Protocol

Indications:
– Lupus nephritis
– Membranous nephropathy
– Minimal change disease
– IgA nephropathy (selected cases)

Initial Dosing:
1. Starting Dose:
– 0.1-0.15 mg/kg/day divided into two doses
– Take on empty stomach (1 hour before or 2 hours after meals)
– Consistent timing important

2. Target Levels:
   – Trough level: 5-10 ng/mL (nephrology indications)
   – Higher levels (10-15 ng/mL) may be used initially

Dose Adjustment:
1. Rapid Adjustments:
– Check level after 3-5 days
– Adjust by 1-2 mg increments
– Recheck in 3-5 days

2. Maintenance:
   – Check levels every 1-2 weeks initially
   – Monthly once stable
   – Adjust for interactions and clinical response

Monitoring:
– Similar to cyclosporine protocol
– Pay special attention to glucose levels (diabetogenic)
– Monitor for tremor and neurological side effects

Plasmapheresis Protocols

Plasmapheresis (plasma exchange) is a critical therapeutic intervention for several nephrology emergencies and specific disease states. Proper coordination with apheresis services and careful monitoring are essential.

Emergency Plasmapheresis Protocol (Anti-GBM Disease)

Indications:
– Anti-GBM disease (Goodpasture’s syndrome)
– Severe ANCA vasculitis with pulmonary hemorrhage
– Thrombotic thrombocytopenic purpura with renal involvement
– Severe lupus with neurological involvement

Pre-procedure Requirements:
1. Laboratory Studies:
– Complete blood count with platelets
– Comprehensive metabolic panel
– Coagulation studies (PT/INR, aPTT)
– Type and screen
– Fibrinogen level

2. Vascular Access:
   – Large-bore central venous catheter (11.5-14 French)
   – Temporary dialysis catheter acceptable
   – Peripheral access rarely adequate

Procedure Protocol:
1. Plasma Volume Calculation:
– Plasma volume = 0.07 × weight (kg) × (1 – hematocrit)
– Standard exchange: 1-1.5 plasma volumes
– Intensive exchange: 1.5-2 plasma volumes

2. Replacement Fluid:
   – 5% albumin (preferred for most indications)
   – Fresh frozen plasma (if coagulopathy present)
   – Combination: 2/3 albumin + 1/3 FFP

3. Anticoagulation:
   – Citrate anticoagulation (preferred)
   – Heparin if citrate contraindicated
   – Monitor ionized calcium during procedure

Daily Plasmapheresis Schedule:
1. Anti-GBM Disease:
– Daily × 10-14 days or until anti-GBM antibodies undetectable
– Continue until creatinine stabilizes
– May extend if pulmonary hemorrhage present

2. ANCA Vasculitis:
   – Daily × 5-7 days for pulmonary hemorrhage
   – Every other day × 2-3 weeks for severe renal disease
   – Individualize based on response

Monitoring During Procedure:
1. Vital Signs:
– Every 15 minutes initially
– Every 30 minutes when stable
– Continuous cardiac monitoring if unstable

2. Laboratory Monitoring:
   – Ionized calcium every 30-60 minutes
   – Platelet count post-procedure
   – Fibrinogen if bleeding concerns

3. Complications to Watch:
   – Hypocalcemia (citrate toxicity)
   – Hypotension
   – Bleeding
   – Allergic reactions to replacement fluid

Post-Procedure Care:
1. Immediate:
– Vital signs every 15 minutes × 1 hour
– Access site assessment
– Laboratory studies (CBC, BMP, Ca²⁺)

2. Medication Timing:
   – Hold immunosuppressive medications until after procedure
   – Resume 2-4 hours post-procedure
   – Adjust for drug removal by plasmapheresis

Emergency Management Protocols

Nephrology emergencies require rapid recognition and immediate intervention. Standardized protocols help ensure optimal outcomes in time-sensitive situations.

Rapidly Progressive Glomerulonephritis (RPGN) Emergency Protocol

Immediate Assessment (within 1 hour):
1. Clinical Evaluation:
– Vital signs and volume status
– Urine output measurement
– Pulmonary examination
– Neurological assessment

2. Laboratory Studies (STAT):
   – Complete blood count
   – Comprehensive metabolic panel
   – Urinalysis with microscopy
   – Anti-GBM antibodies
   – ANCA (c-ANCA/PR3, p-ANCA/MPO)
   – Complement levels (C3, C4)

3. Imaging:
   – Chest X-ray (assess for pulmonary hemorrhage)
   – Renal ultrasound

Immediate Treatment (within 2 hours):
1. High-Dose Corticosteroids:
– Methylprednisolone 500-1000 mg IV daily × 3-5 days
– Start immediately upon clinical suspicion
– Do not wait for biopsy or antibody results

2. Cyclophosphamide:
   – 15 mg/kg IV (max 1.2 g) or
   – 2 mg/kg/day PO
   – Adjust for age and renal function

3. Plasmapheresis (if indicated):
   – Anti-GBM positive: Start immediately
   – Severe ANCA vasculitis: Consider if pulmonary hemorrhage
   – Arrange urgent apheresis consultation

Monitoring Protocol:
1. First 24 hours:
– Vital signs every 4 hours
– Urine output every 4 hours
– Daily weights
– Blood glucose monitoring

2. Daily assessments:
   – Serum creatinine
   – Urinalysis
   – Complete blood count
   – Clinical response evaluation

Pulmonary-Renal Syndrome Emergency Protocol

Immediate Recognition:
– Acute glomerulonephritis + pulmonary hemorrhage
– Hemoptysis with acute kidney injury
– Bilateral pulmonary infiltrates + hematuria

Emergency Interventions (within 1 hour):
1. Airway Management:
– Assess respiratory status
– Oxygen supplementation
– Consider intubation if severe

2. Laboratory Studies:
   – Arterial blood gas
   – Anti-GBM antibodies (STAT)
   – ANCA testing
   – Complete blood count
   – Coagulation studies

3. Imaging:
   – Chest X-ray or CT
   – Assess extent of pulmonary hemorrhage

Treatment Protocol:
1. Immunosuppression:
– Methylprednisolone 1000 mg IV daily
– Cyclophosphamide 15 mg/kg IV
– Start within 2 hours of recognition

2. Plasmapheresis:
   – Daily plasma exchange
   – Continue until anti-GBM undetectable
   – Use FFP replacement if active bleeding

3. Supportive Care:
   – Mechanical ventilation if needed
   – Blood transfusion for severe anemia
   – Avoid anticoagulation

Monitoring and Safety Protocols

Comprehensive monitoring protocols are essential for safe administration of nephrology treatments and early detection of complications.

Immunosuppression Monitoring Protocol

Baseline Assessment:
1. Laboratory Studies:
– Complete blood count with differential
– Comprehensive metabolic panel
– Liver function tests
– Hepatitis B and C serologies
– HIV testing (if indicated)
– Tuberculosis screening
– Urinalysis

2. Imaging:
   – Chest X-ray
   – Consider CT chest if TB risk

3. Vaccinations:
   – Update routine vaccines before starting
   – Avoid live vaccines during treatment

Ongoing Monitoring Schedule:

Weekly for first month:
– Complete blood count
– Serum creatinine
– Liver function tests
– Drug levels (if applicable)

Every 2 weeks for months 2-3:
– Complete blood count
– Basic metabolic panel
– Drug levels

Monthly thereafter:
– Complete blood count
– Comprehensive metabolic panel
– Liver function tests
– Urinalysis
– Drug levels

Quarterly:
– Lipid profile
– Bone density (if on chronic steroids)
– Ophthalmologic exam (if on antimalarials)

Infection Surveillance Protocol

High-Risk Patients:
– Receiving >20 mg prednisone daily
– Multiple immunosuppressive agents
– Recent rituximab or cyclophosphamide

Monitoring:
1. Clinical Assessment:
– Temperature monitoring
– Review of systems for infection
– Physical examination

2. Laboratory Surveillance:
   – Complete blood count
   – Monitor for leukopenia
   – Assess for opportunistic infections

3. Prophylaxis Considerations:
   – Pneumocystis prophylaxis (TMP-SMX)
   – Antiviral prophylaxis (if indicated)
   – Antifungal prophylaxis (high-risk patients)

Drug Interaction Management

Common Interactions in Nephrology:

Calcineurin Inhibitors:
– Monitor levels with new medications
– Adjust doses for CYP3A4 inhibitors/inducers
– Watch for nephrotoxic combinations

Mycophenolate:
– Separate from antacids by 2 hours
– Monitor for increased toxicity with proton pump inhibitors
– Adjust for renal function

Azathioprine:
– Reduce dose with allopurinol
– Monitor for bone marrow suppression
– Check TPMT activity if available

Dose Adjustments for Renal Impairment

Proper dose adjustments for medications in patients with chronic kidney disease are crucial for both efficacy and safety.

Immunosuppressive Dose Adjustments

Mycophenolate Mofetil:
– GFR >60: No adjustment needed
– GFR 30-60: Consider 25% dose reduction
– GFR <30: Reduce dose by 50%
– Dialysis: Give post-dialysis

Azathioprine:
– GFR >50: No adjustment
– GFR 10-50: Reduce dose by 25%
– GFR <10: Reduce dose by 50%

Cyclophosphamide:
– GFR >50: No adjustment for IV dosing
– GFR 25-50: Reduce oral dose by 25%
– GFR <25: Reduce oral dose by 50%

Antimicrobial Adjustments

Trimethoprim-Sulfamethoxazole:
– GFR >30: Standard dosing
– GFR 15-30: Reduce dose by 50%
– GFR <15: Avoid or use with caution

Acyclovir:
– GFR >50: No adjustment
– GFR 25-50: Reduce dose by 50%
– GFR 10-25: Reduce dose by 75%
– GFR <10: Reduce dose by 90%

Quality Assurance and Documentation

Proper documentation and quality assurance measures are essential for safe protocol implementation.

Documentation Requirements

Pre-treatment Documentation:
– Indication for therapy
– Contraindications assessed
– Informed consent obtained
– Baseline laboratory values
– Concurrent medications reviewed

Treatment Documentation:
– Exact doses and timing
– Premedications given
– Monitoring parameters
– Patient response
– Adverse events

Follow-up Documentation:
– Response to therapy
– Laboratory monitoring results
– Dose adjustments made
– Complications encountered
– Long-term outcomes

Quality Improvement Measures

Protocol Adherence:
– Regular audits of protocol compliance
– Feedback to healthcare providers
– Updates based on new evidence

Safety Monitoring:
– Adverse event tracking
– Root cause analysis for complications
– Implementation of safety improvements

Outcome Monitoring:
– Response rates to therapy
– Time to remission
– Long-term outcomes
– Patient satisfaction

Summary

Medical management protocols in nephrology require precise execution of complex treatment regimens with careful attention to safety and monitoring. This chapter provides detailed, step-by-step protocols for the major therapeutic interventions used in nephrology practice.

Intravenous corticosteroid protocols form the foundation of treatment for many acute glomerular diseases, with dosing and duration tailored to the specific indication and severity. High-dose methylprednisolone protocols are essential for rapidly progressive glomerulonephritis and other nephrology emergencies.

Rituximab infusion protocols require careful premedication and monitoring to minimize infusion reactions while maximizing therapeutic benefit. Proper patient selection, screening, and long-term monitoring are crucial for safe administration.

Cyclophosphamide protocols, both intravenous and oral, remain important for severe glomerular diseases. The Euro-Lupus regimen has gained popularity due to reduced toxicity while maintaining efficacy. Proper hydration, mesna administration, and monitoring for complications are essential.

Calcineurin inhibitor protocols require careful dose titration based on drug levels and renal function. Understanding drug interactions and monitoring for nephrotoxicity are crucial for safe long-term use.

Plasmapheresis protocols are life-saving interventions for certain nephrology emergencies, particularly anti-GBM disease and severe ANCA vasculitis with pulmonary hemorrhage. Coordination with apheresis services and proper monitoring are essential.

Emergency management protocols for rapidly progressive glomerulonephritis and pulmonary-renal syndrome emphasize the importance of rapid recognition and immediate treatment initiation. Time-sensitive interventions can be life-saving and kidney-saving.

Comprehensive monitoring protocols ensure early detection of treatment responses and complications. Regular laboratory monitoring, infection surveillance, and drug interaction management are essential components of safe nephrology practice.

These protocols should be used as guides and individualized based on patient-specific factors. Regular updates based on new evidence and institutional experience help ensure optimal patient outcomes while maintaining safety standards.

Oral Corticosteroid Tapering Protocols

Proper tapering of oral corticosteroids is crucial to prevent adrenal insufficiency while minimizing the risk of disease relapse. The tapering schedule depends on the duration of therapy, initial dose, underlying condition, and patient response.

Fast Tapering Protocol (Short-term High-dose Therapy)

Indications:
– Treatment duration <3 weeks
– High-dose therapy for acute conditions
– Patients with minimal risk of relapse
– Need to minimize steroid exposure

Protocol for Initial Dose 60-80 mg/day:
1. Week 1-2: 60-80 mg daily
2. Week 3: 40 mg daily
3. Week 4: 30 mg daily
4. Week 5: 20 mg daily
5. Week 6: 15 mg daily
6. Week 7: 10 mg daily
7. Week 8: 5 mg daily
8. Week 9: Discontinue

Monitoring During Fast Taper:
– Weekly clinical assessment
– Monitor for signs of disease relapse
– Watch for adrenal insufficiency symptoms
– Laboratory monitoring every 1-2 weeks

Protocol for Initial Dose 40 mg/day:
1. Week 1-2: 40 mg daily
2. Week 3: 30 mg daily
3. Week 4: 20 mg daily
4. Week 5: 15 mg daily
5. Week 6: 10 mg daily
6. Week 7: 5 mg daily
7. Week 8: Discontinue

Slow Tapering Protocol (Long-term Therapy)

Indications:
– Treatment duration >3 months
– High risk of disease relapse
– Previous relapse during tapering
– Steroid-dependent conditions

Protocol for Initial Dose 60-80 mg/day:
1. Weeks 1-4: 60-80 mg daily
2. Weeks 5-8: 40 mg daily
3. Weeks 9-12: 30 mg daily
4. Weeks 13-16: 25 mg daily
5. Weeks 17-20: 20 mg daily
6. Weeks 21-24: 17.5 mg daily
7. Weeks 25-28: 15 mg daily
8. Weeks 29-32: 12.5 mg daily
9. Weeks 33-36: 10 mg daily
10. Weeks 37-40: 7.5 mg daily
11. Weeks 41-44: 5 mg daily
12. Weeks 45-48: 2.5 mg daily
13. Week 49: Discontinue

Alternative Slow Taper (Very High Risk):
– Reduce by 10% of current dose every 2-4 weeks
– Once at 10 mg daily, reduce by 1 mg every 2-4 weeks
– Once at 5 mg daily, reduce by 0.5 mg every 2-4 weeks

Alternate-Day Tapering Protocol

Indications:
– Pediatric patients
– Growth concerns
– Steroid-dependent minimal change disease
– Long-term maintenance therapy

Conversion to Alternate-Day:
1. Step 1: Achieve remission on daily dosing
2. Step 2: Convert to alternate-day at same total weekly dose
3. Step 3: Gradually reduce alternate-day dose

Example Conversion:
– Daily 20 mg → Alternate-day 40 mg
– Daily 15 mg → Alternate-day 30 mg
– Daily 10 mg → Alternate-day 20 mg

Alternate-Day Tapering Schedule:
1. Weeks 1-4: 40 mg every other day
2. Weeks 5-8: 35 mg every other day
3. Weeks 9-12: 30 mg every other day
4. Weeks 13-16: 25 mg every other day
5. Weeks 17-20: 20 mg every other day
6. Continue reducing by 5 mg every 4 weeks

Tapering Modifications for Specific Conditions

Lupus Nephritis:
– Slower taper below 20 mg daily
– Consider maintenance at 5-10 mg daily
– Monitor for flare symptoms

ANCA Vasculitis:
– Very slow taper below 15 mg daily
– May require 12-18 months to discontinue
– Close monitoring for relapse

Membranous Nephropathy:
– Moderate taper speed
– Monitor proteinuria closely
– Consider stopping at first sign of relapse

Managing Tapering Complications

Disease Relapse During Taper:
1. Mild Relapse:
– Increase to previous effective dose
– Hold at that dose for 4-6 weeks
– Resume slower taper

2. Severe Relapse:
   – Return to initial high dose
   – Consider alternative immunosuppression
   – Reassess tapering strategy

Adrenal Insufficiency:
1. Symptoms:
– Fatigue, weakness
– Nausea, vomiting
– Hypotension
– Hypoglycemia

2. Management:
   – Return to previous dose
   – Slower tapering schedule
   – Consider morning cortisol testing
   – Stress dose coverage for illness/surgery

Steroid Withdrawal Syndrome:
1. Symptoms:
– Arthralgia, myalgia
– Mood changes
– Fatigue
– Low-grade fever

2. Management:
   – Reassurance and education
   – Slower taper if severe
   – NSAIDs for joint pain
   – Consider temporary dose increase

Kidney Transplant Immunosuppression Protocols

Kidney transplant immunosuppression requires careful balance between preventing rejection and minimizing toxicity. Protocols vary based on immunological risk, donor type, and institutional preferences.

Induction Immunosuppression Protocols

Standard Risk Recipients (Living Donor, Low PRA):

Protocol 1: Basiliximab Induction
1. Basiliximab:
– 20 mg IV on day 0 (within 2 hours of transplant)
– 20 mg IV on day 4 post-transplant
– Premedicate with methylprednisolone 125 mg IV

2. Maintenance Triple Therapy:
   – Tacrolimus: Start 0.1 mg/kg/day divided BID
   – Mycophenolate: 1000 mg BID
   – Prednisone: 20 mg daily, taper per protocol

Protocol 2: No Induction (Low Risk)
1. Immediate Triple Therapy:
– Tacrolimus: 0.15 mg/kg/day divided BID
– Mycophenolate: 1000-1500 mg BID
– Prednisone: 30 mg daily, taper per protocol

High Risk Recipients (Deceased Donor, High PRA, Retransplant):

Protocol 1: Thymoglobulin Induction
1. Thymoglobulin:
– 1.5 mg/kg/day IV × 4-7 days
– Start within 6 hours of transplant
– Premedicate with methylprednisolone 500 mg IV
– Diphenhydramine 25 mg IV
– Acetaminophen 650 mg PO

2. Delayed Tacrolimus:
   – Start when creatinine <3 mg/dL or day 3-5
   – Initial dose: 0.1 mg/kg/day divided BID

3. Maintenance:
   – Mycophenolate: 1000-1500 mg BID
   – Prednisone: 20 mg daily, taper per protocol

Protocol 2: Alemtuzumab Induction
1. Alemtuzumab:
– 30 mg IV × 1 dose intraoperatively
– Premedicate with methylprednisolone 1000 mg IV
– Diphenhydramine 50 mg IV
– Acetaminophen 1000 mg PO

2. Maintenance:
   – Tacrolimus monotherapy initially
   – Add mycophenolate if rejection risk high
   – Steroid-free protocol

Maintenance Immunosuppression Protocols

Standard Triple Therapy:
1. Tacrolimus:
– Target levels: 8-12 ng/mL (months 1-3)
– Target levels: 6-10 ng/mL (months 4-12)
– Target levels: 4-8 ng/mL (>12 months)

2. Mycophenolate:
   – 1000-1500 mg BID
   – Adjust for GI side effects
   – Monitor for leukopenia

3. Prednisone:
   – Month 1: 20 mg daily
   – Month 2: 15 mg daily
   – Month 3: 10 mg daily
   – Month 4-6: 7.5 mg daily
   – Month 7-12: 5 mg daily
   – >12 months: Consider withdrawal

Steroid-Free Protocol:
1. Tacrolimus + Mycophenolate:
– Higher tacrolimus targets initially
– Mycophenolate 1500 mg BID
– Close monitoring for rejection

2. Conversion from Steroids:
   – Gradual withdrawal over 3-6 months
   – Increase other agents temporarily
   – Monitor for rejection

Acute Rejection Treatment Protocols

Mild Acute Cellular Rejection (Banff IA):
1. High-Dose Steroids:
– Methylprednisolone 500 mg IV daily × 3 days
– Return to baseline prednisone dose
– Optimize maintenance immunosuppression

2. Alternative:
   – Prednisone 200 mg daily × 3 days
   – Taper to 20 mg over 1 week
   – Resume maintenance taper

Moderate Acute Cellular Rejection (Banff IB-IIA):
1. High-Dose Steroids:
– Methylprednisolone 500-1000 mg IV daily × 3-5 days
– Consider repeat biopsy if no improvement

2. Optimization:
   – Increase tacrolimus target levels
   – Maximize mycophenolate dose
   – Slow steroid taper

Severe Acute Cellular Rejection (Banff IIB-III):
1. Thymoglobulin:
– 1.5 mg/kg/day IV × 7-14 days
– Monitor CD3 counts (target <20 cells/μL)
– Premedicate for each dose

2. Alternative:
   – Alemtuzumab 30 mg IV × 1-2 doses
   – Consider for steroid-resistant rejection

Antibody-Mediated Rejection:
1. Plasmapheresis:
– Daily × 5-7 sessions
– Replace with 5% albumin
– Monitor for complications

2. IVIG:
   – 2 g/kg divided over 2-5 days
   – Give after plasmapheresis
   – Monitor for volume overload

3. Rituximab:
   – 375 mg/m² weekly × 4 doses OR
   – 1000 mg × 2 doses (days 1 and 15)

4. Bortezomib (Refractory Cases):
   – 1.3 mg/m² IV on days 1, 4, 8, 11
   – Repeat cycle if needed
   – Monitor for neuropathy

Monitoring Protocols for Transplant Recipients

Immediate Post-Transplant (Days 1-7):
– Daily: Creatinine, electrolytes, CBC
– Tacrolimus levels: Daily until stable
– Urine output monitoring
– Daily weights

Early Post-Transplant (Weeks 2-12):
– 2-3 times weekly: Creatinine, electrolytes
– Weekly: CBC, LFTs, tacrolimus level
– Monthly: Lipids, bone profile
– Protocol biopsies (if indicated)

Long-term (>3 months):
– Monthly: Creatinine, electrolytes, CBC
– Every 3 months: Tacrolimus level, lipids
– Annually: Comprehensive metabolic panel
– Cancer screening per guidelines

Hyponatremia Management Protocols

Hyponatremia is one of the most common electrolyte disorders in hospitalized patients. Proper management requires assessment of volume status, chronicity, and severity of symptoms.

Initial Assessment Protocol

Step 1: Confirm True Hyponatremia
– Serum sodium <135 mEq/L
– Rule out pseudohyponatremia (hyperglycemia, hyperlipidemia)
– Check serum osmolality

Step 2: Assess Chronicity
– Acute: <48 hours duration
– Chronic: >48 hours or unknown duration
– Review recent laboratory values
– Obtain detailed history

Step 3: Assess Symptom Severity
– Mild: Asymptomatic or minimal symptoms
– Moderate: Nausea, confusion, headache
– Severe: Seizures, coma, respiratory arrest

Step 4: Determine Volume Status
– Hypovolemic: Dehydration, orthostasis
– Euvolemic: Normal volume status
– Hypervolemic: Edema, heart failure

Treatment Protocols by Category

Severe Symptomatic Hyponatremia (Emergency):

Immediate Treatment:
1. 3% Saline:
– 100-150 mL IV bolus over 10-20 minutes
– May repeat 1-2 times if no improvement
– Goal: Increase sodium by 4-6 mEq/L

2. Calculation for 3% Saline:
   – Desired sodium increase = 4-6 mEq/L
   – Volume of 3% saline = (Desired increase × TBW) / 513
   – TBW = 0.6 × weight (kg) for men, 0.5 × weight for women

3. Monitoring:
   – Check sodium every 2-4 hours
   – Neurological assessments
   – Strict intake/output

Chronic Asymptomatic Hyponatremia:

Hypovolemic Hyponatremia:
1. Normal Saline:
– 1-2 L IV at 125-250 mL/hour
– Monitor response closely
– Goal: 0.5-1 mEq/L/hour increase

2. Monitoring:
   – Sodium every 4-6 hours initially
   – Adjust rate based on response
   – Watch for overcorrection

Euvolemic Hyponatremia (SIADH):
1. Fluid Restriction:
– 800-1000 mL/day initially
– Adjust based on response
– Include all fluid sources

2. Salt Tablets:
   – 1-2 grams TID with meals
   – Increase dietary sodium intake
   – Monitor for volume overload

3. Demeclocycline (if fluid restriction fails):
   – 300-600 mg BID
   – Monitor renal function
   – Avoid in renal impairment

4. Tolvaptan (severe cases):
   – 15 mg daily initially
   – Increase to 30-60 mg daily
   – Hospitalize for initiation
   – Monitor sodium every 6-8 hours

Hypervolemic Hyponatremia:
1. Diuretics:
– Furosemide 20-40 mg IV/PO
– Goal: Negative fluid balance
– Monitor electrolytes closely

2. Fluid Restriction:
   – 1000-1500 mL/day
   – Adjust based on response
   – Consider heart failure management

Correction Rate Guidelines

Safe Correction Rates:
– Acute hyponatremia: 1-2 mEq/L/hour × 3-4 hours, then 0.5-1 mEq/L/hour
– Chronic hyponatremia: 0.5-1 mEq/L/hour, max 8-10 mEq/L/24 hours
– Maximum daily correction: 10-12 mEq/L in 24 hours

High-Risk Patients (slower correction):
– Elderly patients
– Chronic hyponatremia
– Severe malnutrition
– Alcoholism
– Liver disease

Overcorrection Management

Recognition:
– Sodium increase >10-12 mEq/L in 24 hours
– Sodium increase >18 mEq/L in 48 hours
– Development of neurological symptoms

Treatment:
1. Desmopressin (DDAVP):
– 2-4 mcg IV/SC every 6-8 hours
– Promotes water retention
– Monitor sodium closely

2. Free Water Replacement:
   – D5W or hypotonic saline
   – Calculate free water deficit
   – Goal: Lower sodium by 2-3 mEq/L

3. Monitoring:
   – Sodium every 2-4 hours
   – Neurological assessments
   – Adjust therapy based on response

Complete Electrolyte Management Protocols

Electrolyte disorders are common in nephrology patients and require systematic approaches for safe and effective management.

Hyperkalemia Management Protocol

Severity Classification:
– Mild: 5.1-5.9 mEq/L
– Moderate: 6.0-6.4 mEq/L
– Severe: ≥6.5 mEq/L or ECG changes

Emergency Treatment (Severe Hyperkalemia):

Step 1: Cardiac Protection (within 5 minutes)
1. Calcium Gluconate:
– 1-2 ampules (1-2 grams) IV over 2-5 minutes
– Onset: 1-3 minutes, duration: 30-60 minutes
– May repeat if persistent ECG changes

2. Alternative: Calcium Chloride:
   – 0.5-1 ampule (500-1000 mg) IV over 2-5 minutes
   – More potent than gluconate
   – Use central line if possible

Step 2: Shift Potassium Intracellularly (within 15 minutes)
1. Insulin + Glucose:
– Regular insulin 10 units IV + D50W 25 grams (1 ampule)
– Onset: 10-20 minutes, duration: 4-6 hours
– Monitor glucose closely

2. Albuterol:
   – 10-20 mg nebulized over 10 minutes OR
   – 0.5 mg IV over 15 minutes
   – Onset: 30 minutes, duration: 2-4 hours

3. Sodium Bicarbonate (if acidotic):
   – 50-100 mEq IV over 5-10 minutes
   – Only if pH <7.2
   – Onset: 15-30 minutes

Step 3: Remove Potassium from Body
1. Diuretics (if volume overloaded):
– Furosemide 40-80 mg IV
– Onset: 15-30 minutes

2. Sodium Polystyrene Sulfonate (Kayexalate):
   – 15-30 grams PO with sorbitol OR
   – 50 grams in retention enema
   – Onset: 1-2 hours

3. Patiromer (if available):
   – 8.4-25.2 grams daily
   – Onset: 4-7 hours
   – Better tolerated than kayexalate

4. Hemodialysis:
   – Most effective for severe cases
   – Consider if K+ >6.5 mEq/L with ECG changes
   – Arrange emergently

Chronic Hyperkalemia Management:
1. Dietary Modification:
– Low potassium diet (<2-3 grams/day)
– Dietitian consultation
– Patient education

2. Medication Review:
   – Discontinue potassium supplements
   – Adjust ACE inhibitors/ARBs
   – Review other medications

3. Chronic Binders:
   – Patiromer 8.4 grams daily, titrate
   – Sodium zirconium cyclosilicate 10 grams daily
   – Monitor and adjust based on levels

Hypocalcemia Management Protocol

Severity Assessment:
– Mild: 8.0-8.4 mg/dL (ionized 1.0-1.12 mmol/L)
– Moderate: 7.0-7.9 mg/dL (ionized 0.9-0.99 mmol/L)
– Severe: <7.0 mg/dL (ionized <0.9 mmol/L) or symptomatic

Acute Symptomatic Hypocalcemia:

Emergency Treatment:
1. Calcium Gluconate:
– 1-2 ampules (1-2 grams) in 50-100 mL D5W or NS
– Infuse over 10-20 minutes
– May repeat every 6 hours as needed

2. Calcium Chloride (if severe):
   – 0.5-1 ampule (500-1000 mg) in 50-100 mL D5W
   – Infuse over 10-20 minutes via central line
   – More potent than gluconate

Continuous Infusion (if recurrent symptoms):
1. Calcium Gluconate Drip:
– 6 ampules (6 grams) in 500 mL D5W or NS
– Start at 25-50 mL/hour (0.3-0.6 mg/kg/hour)
– Titrate based on symptoms and levels

Chronic Hypocalcemia Management:
1. Oral Calcium:
– Calcium carbonate 1-2 grams TID with meals
– Calcium citrate if achlorhydric
– Separate from other medications

2. Vitamin D Supplementation:
   – Calcitriol 0.25-0.5 mcg BID
   – Paricalcitol 1-2 mcg daily
   – Monitor for hypercalciuria

3. Magnesium Replacement (if deficient):
   – Magnesium oxide 400 mg BID
   – Magnesium sulfate 1-2 grams IV if severe

Hyperphosphatemia Management Protocol

Target Levels:
– CKD Stage 3-4: <4.6 mg/dL
– CKD Stage 5: <5.5 mg/dL
– Dialysis patients: 3.5-5.5 mg/dL

Acute Management:
1. Hemodialysis:
– Most effective for severe cases
– Consider if phosphorus >10 mg/dL
– Arrange urgently if symptomatic

2. Phosphate Binders:
   – Calcium carbonate 1-2 grams with meals
   – Sevelamer 800-1600 mg with meals
   – Lanthanum 500-1000 mg with meals

Chronic Management:
1. Dietary Restriction:
– Limit phosphorus to 800-1000 mg/day
– Avoid processed foods
– Dietitian consultation

2. Phosphate Binders (titrate to effect):
   – Calcium-based: Calcium carbonate, calcium acetate
   – Non-calcium: Sevelamer, lanthanum, iron-based
   – Dosing: Start low, titrate every 2-4 weeks

3. Monitoring:
   – Monthly phosphorus levels
   – Calcium-phosphorus product <55
   – Adjust binder doses accordingly

FSGS Treatment Guidelines and Protocols

Focal segmental glomerulosclerosis (FSGS) treatment decisions require careful assessment of risk factors, disease activity, and potential for progression.

When to Treat FSGS in Adults

Absolute Indications for Treatment:
1. Nephrotic Syndrome:
– Proteinuria >3.5 g/day
– Hypoalbuminemia <3.0 g/dL
– Edema present

2. Progressive Renal Function Decline:
   – >25% decline in GFR over 6-12 months
   – Doubling of serum creatinine
   – Slope of GFR decline >5 mL/min/1.73m²/year

3. Severe Proteinuria with Risk Factors:
   – Proteinuria >1 g/day with hypertension
   – Proteinuria >1 g/day with declining GFR
   – Young age with significant proteinuria

Relative Indications:
1. Moderate Proteinuria (1-3.5 g/day):
– Consider if young age
– Consider if family history of ESRD
– Consider if genetic variants present

2. Asymptomatic Proteinuria:
   – Generally observe
   – Optimize supportive care
   – Consider treatment if progression

Contraindications to Immunosuppression:
1. Advanced CKD:
– GFR <30 mL/min/1.73m² (relative)
– GFR <15 mL/min/1.73m² (absolute)
– Extensive glomerulosclerosis (>50%)

2. Active Infections:
   – Systemic bacterial infections
   – Opportunistic infections
   – Recent live virus vaccination

3. Malignancy:
   – Active malignancy
   – Recent cancer treatment
   – High risk for malignancy

Risk Stratification for FSGS Treatment

High-Risk Features (Favor Treatment):
– Age <40 years
– Nephrotic syndrome at presentation
– Minimal chronic changes on biopsy
– Absence of hypertension
– Normal or mildly reduced GFR
– Absence of genetic mutations

Low-Risk Features (Consider Observation):
– Age >65 years
– Non-nephrotic proteinuria
– Extensive chronic changes on biopsy
– Longstanding hypertension
– Significantly reduced GFR
– Genetic FSGS variants

FSGS Treatment Protocols

First-Line Treatment: Corticosteroids

High-Dose Prednisone Protocol:
1. Induction Phase:
– Prednisone 1 mg/kg/day (max 80 mg) × 4-6 months
– Take as single morning dose
– Continue until remission or maximum duration

2. Tapering Phase:
   – Reduce by 10 mg every 2 weeks until 40 mg
   – Reduce by 5 mg every 2 weeks until 20 mg
   – Reduce by 2.5 mg every 2 weeks until 10 mg
   – Reduce by 1 mg every 2 weeks until discontinuation

3. Response Assessment:
   – Complete remission: Proteinuria <0.3 g/day
   – Partial remission: >50% reduction, <3.5 g/day
   – No response: <50% reduction in proteinuria

Alternative Steroid Protocol (Elderly/High Risk):
1. Modified Dose:
– Prednisone 0.5-0.75 mg/kg/day × 3-4 months
– Slower tapering schedule
– Close monitoring for complications

Second-Line Treatments (Steroid-Resistant/Intolerant):

Calcineurin Inhibitor Protocol:
1. Cyclosporine:
– Starting dose: 3-5 mg/kg/day divided BID
– Target trough level: 100-200 ng/mL
– Duration: 6-12 months minimum

2. Tacrolimus:
   – Starting dose: 0.1-0.15 mg/kg/day divided BID
   – Target trough level: 5-10 ng/mL
   – Duration: 6-12 months minimum

3. Monitoring:
   – Drug levels every 1-2 weeks initially
   – Monthly once stable
   – Monitor renal function closely

Mycophenolate Mofetil Protocol:
1. Dosing:
– 1000-1500 mg BID
– Start with lower dose if GI intolerance
– May combine with low-dose steroids

2. Monitoring:
   – Complete blood count every 2 weeks × 3 months
   – Monthly thereafter
   – Adjust dose for leukopenia

Rituximab Protocol (Refractory Cases):
1. Standard Regimen:
– 375 mg/m² weekly × 4 doses OR
– 1000 mg on days 1 and 15

2. Premedication:
   – Methylprednisolone 100 mg IV
   – Diphenhydramine 25 mg IV
   – Acetaminophen 650 mg PO

3. Monitoring:
   – B-cell depletion assessment
   – Immunoglobulin levels
   – Infection surveillance

Supportive Care Protocol for FSGS

ACE Inhibitor/ARB Therapy:
1. Indications:
– All FSGS patients with proteinuria
– Regardless of blood pressure
– Start early in disease course

2. Dosing:
   – Lisinopril 10-40 mg daily OR
   – Losartan 50-100 mg daily
   – Titrate to maximum tolerated dose

3. Monitoring:
   – Serum creatinine and potassium in 1 week
   – Adjust dose if creatinine increases >30%

Lipid Management:
1. Targets:
– LDL cholesterol <100 mg/dL
– <70 mg/dL if high cardiovascular risk

2. Therapy:
   – Atorvastatin 20-80 mg daily
   – Rosuvastatin 10-40 mg daily
   – Monitor for myopathy

Edema Management:
1. Diuretics:
– Furosemide 20-80 mg daily
– Increase dose for refractory edema
– Consider combination therapy

2. Dietary Modifications:
   – Sodium restriction (2-3 g/day)
   – Protein intake 0.8-1.0 g/kg/day
   – Fluid restriction if hyponatremic

Monitoring Protocol for FSGS Treatment

Baseline Assessment:
– Complete blood count
– Comprehensive metabolic panel
– Liver function tests
– Lipid profile
– Urinalysis with microscopy
– 24-hour urine protein and creatinine
– Hepatitis B and C serologies
– Tuberculosis screening

During Treatment:
Weeks 1-4:
– Weekly: Creatinine, electrolytes, CBC
– Bi-weekly: Urinalysis, spot protein/creatinine
– Monthly: Comprehensive metabolic panel

Months 2-6:
– Bi-weekly: Creatinine, electrolytes
– Monthly: CBC, urinalysis, protein/creatinine
– Every 3 months: Comprehensive assessment

Long-term Follow-up:
– Monthly: Creatinine, electrolytes, proteinuria
– Every 3 months: CBC, comprehensive panel
– Every 6 months: Lipids, bone profile
– Annually: Cardiovascular risk assessment

Treatment Response and Outcomes

Expected Response Rates:
– Complete remission: 20-30% with steroids
– Partial remission: 20-40% with steroids
– No response: 40-60% with steroids

Factors Predicting Response:
– Good response: Young age, minimal chronic changes
– Poor response: Older age, extensive sclerosis, genetic variants

Long-term Management:
– Responders: Gradual immunosuppression withdrawal
– Non-responders: Focus on supportive care
– Relapsers: Consider alternative agents or combination therapy

Clinical Pearls

1. Steroid Tapering Safety: Never stop steroids abruptly after >3 weeks of therapy – risk of adrenal crisis. When in doubt, taper slower rather than faster.

2. 3% Saline Calculation: For severe hyponatremia, 100 mL of 3% saline raises sodium by ~2 mEq/L in a 70 kg patient. Check sodium every 2 hours during correction.

3. Hyperkalemia ECG Changes: Peaked T-waves appear at K+ >6.0, QRS widening at >7.0, sine wave pattern at >8.0. Calcium works in minutes but doesn’t lower potassium.

4. Transplant Drug Levels: Tacrolimus levels should be drawn 12 hours after the last dose (trough level). Higher levels needed early post-transplant (8-12 ng/mL).

5. FSGS Treatment Duration: Steroids need 4-6 months trial in FSGS before declaring resistance. Many patients respond late compared to minimal change disease.

6. Rituximab Premedication: Always premedicate with steroids, antihistamines, and acetaminophen. First infusion reactions are most common – start slow.

7. Cyclophosphamide Hydration: Adequate hydration (2-3 L/day) and morning dosing reduce hemorrhagic cystitis risk. Mesna needed for high doses (>1 g/m²).

8. Hyponatremia Correction: Maximum safe correction is 8-10 mEq/L in 24 hours. Overcorrection can cause osmotic demyelination syndrome.

9. Calcineurin Inhibitor Nephrotoxicity: Rising creatinine with therapeutic drug levels suggests nephrotoxicity. Reduce dose by 25-50% and recheck.

10. Transplant Rejection Timing: Acute cellular rejection peaks at 1-6 months post-transplant. Late rejection (>1 year) often indicates medication non-adherence.

11. Phosphate Binder Timing: Must be taken with meals to be effective. Calcium-based binders can cause hypercalcemia – monitor calcium-phosphorus product.

12. Emergency Hyperkalemia: Calcium protects the heart but doesn’t lower potassium. Insulin + glucose shifts K+ intracellularly. Dialysis removes K+ from the body.

Recommended Diagrams and Images:

1. Steroid Tapering Flowcharts: Visual algorithms for fast vs slow tapering based on duration and risk factors
2. Hyponatremia Management Algorithm: Decision tree based on volume status, chronicity, and symptom severity
3. Hyperkalemia Emergency Protocol: Step-by-step visual guide with timing and dosing
4. Transplant Immunosuppression Timeline: Visual representation of induction, maintenance, and monitoring schedules
5. FSGS Treatment Decision Tree: Algorithm for when to treat based on risk factors and disease severity
6. Drug Level Monitoring Charts: Target ranges and adjustment protocols for tacrolimus, cyclosporine
7. Electrolyte Correction Formulas: Visual reference cards for common calculations
8. Rituximab Infusion Rate Chart: Step-by-step infusion protocol with reaction management
9. Rejection Treatment Protocols: Visual comparison of treatments for different rejection types
10. Phosphate Binder Comparison Table: Efficacy, side effects, and dosing for different binders

Laboratory Reference Images:

• ECG changes in hyperkalemia progression
• Transplant biopsy findings for different rejection types
• Drug level monitoring graphs and target ranges
• Electrolyte correction nomograms

Clinical Photography:

• Signs of steroid side effects (cushingoid features, striae)
• Volume status assessment techniques
• Transplant surgical site monitoring
• Signs of drug toxicity (calcineurin inhibitor effects)

Monitoring Flow Sheets:

• Post-transplant monitoring schedules
• Immunosuppression adjustment protocols
• Electrolyte management tracking sheets
• Treatment response assessment forms

Slide 1: Title Slide

• Title: Medical Management Protocols in Nephrology
• Subtitle: Essential Protocols for Safe and Effective Patient Care
• NephroHub Watermark

Slide 2: Learning Objectives

• Master steroid tapering protocols
• Implement transplant immunosuppression safely
• Manage electrolyte emergencies effectively
• Apply evidence-based FSGS treatment guidelines
• Execute complex drug protocols with confidence

Slide 3: Protocol Implementation Principles

• Safety First: Always assess contraindications
• Individualization: Adjust for patient factors
• Monitoring: Follow established schedules
• Documentation: Record all interventions
• Team Approach: Coordinate with pharmacy and nursing

Slide 4: Steroid Tapering Overview

• Fast Taper: <3 weeks therapy, low relapse risk
• Slow Taper: >3 months therapy, high relapse risk
• Alternate Day: Pediatric patients, growth concerns
• Never Stop Abruptly: Risk of adrenal insufficiency

Slide 5: Steroid Tapering Schedules

• Fast taper: 60→40→30→20→15→10→5→0 (weekly reductions)
• Slow taper: 10% reduction every 2-4 weeks
• Critical threshold: Slow taper below 20 mg daily
• Monitor for relapse and adrenal insufficiency

Slide 6: Transplant Immunosuppression Strategy

• Induction: Prevent early rejection
• Maintenance: Long-term graft protection
• Rejection Treatment: Rescue therapy
• Risk Stratification: Tailor to patient factors

Slide 7: Transplant Induction Protocols

• Low Risk: Basiliximab or no induction
• High Risk: Thymoglobulin or alemtuzumab
• Delayed Graft Function: Avoid calcineurin inhibitors initially
• Premedication: Essential for antibody therapy

Slide 8: Maintenance Immunosuppression

• Triple Therapy: Tacrolimus + MMF + Prednisone
• Target Levels: Higher early, lower long-term
• Steroid Withdrawal: Consider after 6-12 months
• Drug Interactions: Monitor closely

Slide 9: Rejection Treatment Protocols

• Cellular Rejection: High-dose steroids first-line
• Antibody-Mediated: Plasmapheresis + IVIG + rituximab
• Severe Rejection: Thymoglobulin or alemtuzumab
• Monitoring: Repeat biopsy if no response

Slide 10: Hyponatremia Assessment

• Confirm True Hyponatremia: Rule out pseudohyponatremia
• Assess Chronicity: <48 hours vs >48 hours
• Symptom Severity: Mild, moderate, severe
• Volume Status: Hypo-, eu-, hypervolemic

Slide 11: Hyponatremia Treatment by Category

• Severe Symptomatic: 3% saline bolus
• Hypovolemic: Normal saline replacement
• SIADH: Fluid restriction, salt tablets
• Hypervolemic: Diuretics, fluid restriction

Slide 12: Hyponatremia Correction Rates

• Acute: 1-2 mEq/L/hour × 3-4 hours
• Chronic: 0.5-1 mEq/L/hour, max 8-10 mEq/L/24h
• High Risk: Slower correction rates
• Overcorrection: DDAVP + free water

Slide 13: Hyperkalemia Emergency Management

• Step 1: Cardiac protection (calcium)
• Step 2: Shift intracellularly (insulin + glucose)
• Step 3: Remove from body (diuretics, binders, dialysis)
• Monitoring: ECG changes, repeat K+ levels

Slide 14: Hyperkalemia Treatment Agents

• Calcium: Cardioprotective, works in minutes
• Insulin + Glucose: Shifts K+ intracellularly
• Albuterol: β2-agonist effect
• Dialysis: Most effective removal method

Slide 15: Chronic Electrolyte Management

• Hyperkalemia: Diet, binders, medication adjustment
• Hypocalcemia: Calcium supplements, vitamin D
• Hyperphosphatemia: Binders, dietary restriction
• Target Levels: CKD stage-specific goals

Slide 16: FSGS Treatment Indications

• Absolute: Nephrotic syndrome, declining GFR
• Relative: Moderate proteinuria with risk factors
• Contraindications: Advanced CKD, active infection
• Risk Stratification: Age, biopsy findings, genetics

Slide 17: FSGS Treatment Protocols

• First-Line: High-dose prednisone × 4-6 months
• Second-Line: Calcineurin inhibitors, MMF
• Refractory: Rituximab, combination therapy
• Supportive: ACE inhibitors, lipid management

Slide 18: FSGS Response Assessment

• Complete Remission: Proteinuria <0.3 g/day
• Partial Remission: >50% reduction, <3.5 g/day
• No Response: <50% reduction
• Time Frame: 4-6 months for steroid trial

Slide 19: Drug Monitoring Essentials

• Tacrolimus: 12-hour trough levels
• Cyclosporine: Trough or 2-hour post-dose
• MMF: CBC monitoring for leukopenia
• Rituximab: B-cell depletion, immunoglobulins

Slide 20: Safety Monitoring Protocols

• Baseline: Complete assessment before starting
• Frequent Early: Weekly monitoring initially
• Long-term: Monthly to quarterly monitoring
• Drug-Specific: Tailored to agent toxicities

Slide 21: Emergency Protocols Summary

• RPGN: Steroids + cyclophosphamide + plasmapheresis
• Severe Hyponatremia: 3% saline with careful monitoring
• Hyperkalemia: Calcium, insulin, dialysis if severe
• Rejection: High-dose steroids, escalate if needed

Slide 22: Common Protocol Errors

• Steroid Tapering: Too fast, abrupt discontinuation
• Hyponatremia: Overcorrection, wrong fluid choice
• Hyperkalemia: Forgetting glucose with insulin
• Transplant: Wrong drug levels, missed interactions

Slide 23: Quality Assurance

• Standardized Orders: Reduce variation and errors
• Monitoring Checklists: Ensure complete assessment
• Team Communication: Coordinate care effectively
• Documentation: Record all interventions

Slide 24: Case-Based Applications

• Complex transplant patient management
• Emergency electrolyte correction
• FSGS treatment decision-making
• Multi-drug protocol coordination

Slide 25: Key Takeaways

• Safety First: Always assess risks and contraindications
• Individualize: Adjust protocols for patient factors
• Monitor Closely: Follow established schedules
• Team Approach: Coordinate with all team members
• Continuous Learning: Update protocols with new evidence

Question 1

What is the maximum safe rate of sodium correction in chronic hyponatremia?

A) 2-4 mEq/L per hour
B) 0.5-1 mEq/L per hour, maximum 8-10 mEq/L per 24 hours
C) 1-2 mEq/L per hour, no daily limit
D) 4-6 mEq/L per hour for the first 4 hours
E) No specific limits if patient is symptomatic

Correct Answer: B) 0.5-1 mEq/L per hour, maximum 8-10 mEq/L per 24 hours

Explanation: Chronic hyponatremia should be corrected slowly to prevent osmotic demyelination syndrome. The maximum safe correction is 8-10 mEq/L in 24 hours.

Question 2

Which medication provides immediate cardiac protection in severe hyperkalemia?

A) Insulin and glucose
B) Sodium bicarbonate
C) Calcium gluconate
D) Albuterol
E) Furosemide

Correct Answer: C) Calcium gluconate

Explanation: Calcium gluconate provides immediate cardiac membrane stabilization in severe hyperkalemia, working within 1-3 minutes, though it doesn’t lower the potassium level.

Question 3

What is the standard starting dose of tacrolimus in kidney transplant recipients?

A) 0.05 mg/kg/day
B) 0.1-0.15 mg/kg/day
C) 0.2-0.3 mg/kg/day
D) 0.5 mg/kg/day
E) 1 mg/kg/day

Correct Answer: B) 0.1-0.15 mg/kg/day

Explanation: The standard starting dose of tacrolimus in kidney transplant recipients is 0.1-0.15 mg/kg/day divided into two doses, with higher doses used in high-risk patients.

Question 4

How long should steroids be continued in FSGS before declaring steroid resistance?

A) 2-4 weeks
B) 6-8 weeks
C) 3 months
D) 4-6 months
E) 12 months

Correct Answer: D) 4-6 months

Explanation: FSGS requires a longer steroid trial than minimal change disease. Patients should receive high-dose prednisone for 4-6 months before being declared steroid-resistant.

Question 5

What is the first-line treatment for mild acute cellular rejection in kidney transplant?

A) Thymoglobulin
B) Plasmapheresis
C) High-dose methylprednisolone
D) Rituximab
E) Increased tacrolimus dose only

Correct Answer: C) High-dose methylprednisolone

Explanation: High-dose methylprednisolone (500-1000 mg IV daily for 3-5 days) is the first-line treatment for acute cellular rejection in kidney transplant recipients.

Question 6

Which premedication is essential before rituximab infusion?

A) Antibiotics only
B) Antihistamines only
C) Corticosteroids, antihistamines, and acetaminophen
D) Calcium and magnesium
E) Proton pump inhibitors

Correct Answer: C) Corticosteroids, antihistamines, and acetaminophen

Explanation: Standard premedication for rituximab includes methylprednisolone 100 mg IV, diphenhydramine 25-50 mg, and acetaminophen 650-1000 mg to prevent infusion reactions.

Question 7

What is the target tacrolimus trough level in the first 3 months post-transplant?

A) 2-5 ng/mL
B) 4-8 ng/mL
C) 8-12 ng/mL
D) 12-15 ng/mL
E) 15-20 ng/mL

Correct Answer: C) 8-12 ng/mL

Explanation: Higher tacrolimus levels (8-12 ng/mL) are targeted in the first 3 months post-transplant when rejection risk is highest, then gradually reduced to 4-8 ng/mL long-term.

Question 8

What is the most serious complication of rapid sodium correction in chronic hyponatremia?

A) Cerebral edema
B) Osmotic demyelination syndrome
C) Seizures
D) Cardiac arrhythmias
E) Pulmonary edema

Correct Answer: B) Osmotic demyelination syndrome

Explanation: Osmotic demyelination syndrome (central pontine myelinolysis) is the most serious complication of overly rapid correction of chronic hyponatremia, potentially causing permanent neurological damage.

Question 9

Which electrolyte abnormality requires immediate treatment regardless of symptoms?

A) Sodium 130 mEq/L
B) Potassium 6.8 mEq/L with ECG changes
C) Calcium 7.5 mg/dL
D) Phosphorus 8.0 mg/dL
E) Magnesium 1.2 mg/dL

Correct Answer: B) Potassium 6.8 mEq/L with ECG changes

Explanation: Severe hyperkalemia with ECG changes represents a cardiac emergency requiring immediate treatment with calcium for cardiac protection, regardless of symptoms.

Question 10

What is the minimum duration of cyclophosphamide-induced amenorrhea that suggests permanent ovarian failure?

A) 3 months
B) 6 months
C) 12 months
D) 18 months
E) 24 months

Correct Answer: C) 12 months

Explanation: Cyclophosphamide-induced amenorrhea lasting 12 months or longer suggests permanent ovarian failure, particularly in women over 30 years of age. This emphasizes the importance of fertility counseling before treatment.

Visual Learning Workflow